Key facts
- It has raised $190K; the latest was PE Growth/Expansion ($190K) in Apr 2025.
- Notable investors include Piramal Fund Management.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Sai Mirra Innopharm
- ·The full record, as it builds
Funding rounds
No funding rounds for Sai Mirra Innopharm are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sai Mirra Innopharm
Manufacturer and developer of a prominent pharmacy catering to the needs of pharmaceutical distributors, healthcare providers, and regulatory bodies. The company provides prescription medications, neurological drugs, gout management, and antihistamines, thereby improving healthcare globally.
- Sector
- Healthcare
- HQ
- Chennai, India
- Founded
- 2001
- Employees
- 446
- Website
- saimirra.com/
- Ownership
- Privately Held (backing)
Sai Mirra Innopharm doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sai Mirra Innopharm shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sai Mirra Innopharm in its N-PORT filings yet. We sweep new filings monthly.